Introduction The products of the serotonin receptor genes are important targets for conventional and atypical antipsychotics, and may be relevant for antipsychotic activity and associated adverse reactions. It has been shown that the high potency at 5-HT2 receptors may also be associated with the production of moderate extrapyramidal side effects (EPS). In addition, serotonin neurotransmitter systems in the central nervous system play an important role in eating behaviours, and are involved in the symptomatology related to the metabolic syndrome, including obesity, diabetes and hyperlipidemia.
Materials and methods This study was designed to investigate the hypothesis that serotonin pathway genes play a part in mediating antipsychotic-induced adverse reactions, including EPS, tardive dyskinesia, obesity and diabetes. Polymorphisms in the 5-HT2A (102 (T/C), His452Tyr), 5-HT2C (Cys23Ser, -759 (C/T), -995 (G/A), TPH2 (-366 (C/T), -8933 (A/G) and 5-HTT (LPR, -15370 (A/G)) genes were investigated in a cohort of 427 US Caucasian patients undergoing antipsychotic treatment, using automated genotyping techniques.
Results 5-HTT (LPR) and 5-HT2A (102 (T/C) polymorphisms were found to be associated with BMI (P = 0.05 and 0.005, respectively). The genotype distribution of the TPH2-366 (T/C) polymorphism was found to be significantly associated with the presence of diabetes (P = 0.01). A trend towards an association (P = 0.07) between the 5-HT2C Cys23Ser polymorphism and tardive dyskinesia was found when age, duration of treatment, dose and sex were considered. Genotype distributions of the 5-HT2C -995 (G/A), 5-HT2C -759 (C/T) and 5-HT2A His452Tyr polymorphisms differed among patients presenting EPS and those without (P = 0.08, 0.06 and 0.08, respectively) . No other statistically significant associations were observed. 
Conclusion

Introduction
The efficacy of antipsychotics in alleviating the symptoms of schizophrenia can be marred by the appearance of adverse reactions. These unwanted drug effects can be wide ranging to include extrapyramidal side effects (EPS), tardive dyskinesia (TD), weight gain and diabetes, among others, depending on the degree and type of drug-receptor interactions. The products of the serotonin genes are important targets for conventional and atypical antipsychotics (Meltzer, 1999; Meltzer et al., 2003; Miyamoto et al., 2005) , and may be relevant for antipsychotic activity and associated adverse reactions. There have been some reports associating the use of the antidepressant selective serotonin reuptake inhibitors with the development of EPS (Schillevoort et al., 2002) . In addition, serotonin neurotransmitter systems in the central nervous system play an important role in eating behaviours, and are involved in the symptomatology related to metabolic syndrome, including obesity, diabetes and hyperlipidemia. Contributing to this hypothesis, it has been reported that the metabolic syndrome is associated with diminished brain serotonergic activity (Muldoon et al., 2006) .
It has been suggested that genetic, in addition to environmental and clinical, causes are responsible for the interindividual variability in the presentations of these adverse reactions (Eichelbaum and Evert, 1996; Lerer and Segman, 2006) . Several gene associations have been reported confirming this hypothesis. CYP2D6 variants have been associated with the adverse reactions of risperidone (De Leon et al., 2005a) , including TD, as well as other extrapyramidal symptoms, in various population groups (Arthur et al., 1995; Inada et al., 2003; Liou et al., 2004) . Another proven and genetically driven association of adverse reactions is that with a Ser9Gly polymorphism in the dopamine receptor type 3 (D3) gene. Several investigators have reported a significant association of D3 Ser9Gly with TD (Steen et al., 1997; Lerer et al., 2002; Bakker et al., 2006) and akathisia (Eichhammer et al., 2000) after treatment with antipsychotics. However, relatively fewer studies have investigated the possible role of the serotonin pathway genes in mediating antipsychotic-induced adverse reactions. There have been some reports associating variants in serotonin receptors with drug-induced TD (Zhang et al., 2002; Lerer et al., 2005) and EPS (Gunes et al., 2007) . Other studies found an association of 5-HT2C receptor gene (HTR2C) variants with weight gain after antipsychotic therapy (Reynolds et al., 2003; Ellingrod et al., 2005; Miller et al., 2005) . However, there is a shortage of published work investigating the role of the 5-HT2A and 5-HT2C serotonin receptors with the wider range of side effects experienced by patients on antipsychotics. Moreover, research is required to discern the contribution of other important genes in the serotonergic pathway system such as the serotonin transporter gene (SLC6A4) and the gene coding for the enzyme tryptophan hydroxylase subtype 2 (TPH2), which plays a ratelimiting role in the biosynthesis of serotonin. This study was designed to investigate the hypothesis that serotonin pathway genes play a part in mediating antipsychotic-induced adverse reactions, including EPS, TD, obesity and diabetes. A total of nine polymorphisms in the selected genes HTR2C, SLC6A4, TPH2 and in the gene coding for the 5-HT2A receptor (HTR2A) were investigated, using a sample of 427 US Caucasian patients who had received antipsychotic treatment.
Materials and methods
Clinical sample
A total of 427 US Caucasian patients were included in the study. These patients were either receiving risperidone, or had risperidone prescribed to them but discontinued taking it because of adverse reactions and were receiving alternative antipsychotic medication (Table 1) . Patient characteristics and side effects were assessed cross-sectionally and recorded in detail elsewhere (De Leon et al., 2005a , 2005b Susce et al., 2005) . Details of patients' demographics and adverse reactions relevant to this study are given in Table 1 . The Abnormal Involuntary Movement Scale (Guy, 1976 ) was used to assess dyskinetic movements. Reversible EPS were rated with the English version of the Udvalg for Kliniske Undersogelser (Lingjaerde et al., 1987) . TD was considered to be present when there were mild movements in at least two body areas or moderate movements in at least one body area in one examination [this is a modification of the criteria by Schooler and Kane (1982) 
Polymorphism selection and genotyping
Common polymorphisms that were described earlier and had been reported to be associated with response to psychiatric treatment were chosen to represent the selected genes (Arranz and De Leon, 2007) , with the exception of TPH2 in which the HapMap programme was used for single nucleotide polymorphism (SNP) selection in the promoter region of the gene. These chosen markers were the HTR2A 102(T/C) (rs6313) and His452Tyr (rs6314) SNPs, the HTR2C-995(G/A) (rs3813928), -759(C/T) (rs3813929) and Cys23Ser (rs6318) SNPs, the TPH2-8933(A/G) (rs17110451) and -366(C/T) (rs4448731) SNPs, and on SLC6A4, the polymorphic repeat LPR and the -15370(A/G) (rs25531) SNP. Although no individual association has been described with the SLC6A4 rs25331 polymorphism, it has been reported to influence the functional effect of the LPR polymorphism in the same gene and for this reason has been included (Wendland et al., 2006) . The 5-HT2A 102 (T/C) polymorphism is in nearly complete linkage disequilibrium (LD) with a -1438 (G/A) polymorphism in the promoter region of the same gene (Arranz and De Leon, 2007) and provides similar information. For this reason, only one of the polymorphisms was genotyped.
As reliable genotyping assays already existed for it, we decided to characterize the 102 (T/C) variant in our sample. We performed genotyping of the samples using ABI technology by a commercial company (KBioscience, Hoddesdon, Hertfordshire, UK) following our sequence information and were blind to the clinical data. The different numbers of samples genotyped across polymorphisms were a result of sample exhaustion or repeated assay failure.
Statistical analysis
Statistical analyses were done using the statistical packages SPSS V13.0 (SPSS Inc., Chicago, Illinois, USA) and EPiInfo V6.0 (CDC, Atlanta, Georgia, USA). The influence of polymorphisms on side effects was evaluated by regression and w 2 analyses. For regression analyses, the investigated polymorphism was treated as an independent variable and the clinical parameters as dependent variables. Factors likely to affect clinical outcome (age of onset, duration of treatment, dose, sex) were included as covariates. Probabilities of r 0.05 were regarded as being significant, and a correction of 20 (five clinical classifications Â four genes) for multiple analyses was applied. Haplotype analyses were done using the GeneCounting programme (Zhao et al., 2002) . This sample has a 95% power to detect genetic associations with odds ratio of 2 (95% confidence interval) for polymorphisms with a minimal allele frequency of 0.20 in relation to BMI, presence of EPS and TD and a 90% power in relation to presence of diabetes.
Results
With the exception of SLC6A4 -15370(A/G), the genotype distribution of all other polymorphisms obeyed the Hardy-Weinberg equilibrium. The significant departure of the genotype distribution of SLC6A4 -15370(A/G) from Hardy-Weinberg equilibrium was because of the presence of an excess of rare allele homozygotes (G/G). Although genotyping error is one possibility behind this departure, the fact that our clinical sample consists entirely of patients, and in that respect is different from the rest of the population, must be borne in mind. Sex had no significant influence on the genotype distribution of the polymorphisms on HTR2A, SLC6A4 and TPH2. In contrast, HTR2C, being located on the X chromosome, necessitated a different interpretation of the combined sex results.
HTR2A
Association analyses of the two markers (102 (T/C) and His452Tyr) on this gene against the various adverse reactions are presented in Table 2 . No significant association at the P value of less than 0.05 level was observed between His452Tyr and any of the adverse reactions, although a trend towards association was observed between the His452Tyr genotype and the presence or absence of EPS (w 2 =4.97, P=0.08). The genotypes at 102 (T/C), however, yielded significant association with BMI (P=0.005), after correcting for age, dose, duration of medication and sex. These associations became trends when correction for multiple analyses was applied. Patients possessing two copies of the T-allele seem to have higher BMI values (P=0.04). No other significant association with other adverse reactions was observed.
HTR2C
For w 2 comparisons of genotypes of this X-located gene, heterozygote females and all (male and female) homozygotes for the rare variants were grouped together. For allele analyses, the total number of alleles in males and females was considered. The -995(G/A) and -759(C/T) polymorphisms were in near complete LD, with alleles -995-G and -759-C, very likely to be transmitted together. Only three individuals were found to deviate from this pattern. Chi-square analyses did not reveal significant associations between the -995(G/A) marker on this gene and adverse reactions (refer to Table 2), although a trend towards association with the presence of EPS (P=0.08) was observed. Similarly, the genotype and allele distributions of the -759(C/T) polymorphism showed a trend towards association with EPS (P=0.06 and 0.08, respectively) but no other statistically significant correlation. Logistic regression including age, dose, treatment duration and sex as covariates also failed to relate genotype and adverse reactions. The genotype at the Cys23Ser marker showed a trend towards association with the presence of TD (P=0.07 for both, allele and genotype distribution), and a trend towards association with the presence of diabetes when cofactors were considered (P=0.09) but no significant association with any of the other side effects was noted.
TPH2
Single polymorphism association analyses of the two markers investigated on this gene against the adverse reactions are given in Table 2 . The presence of diabetes was the only adverse reaction that yielded significant association with the genotypes of the -366 (T/C) marker (P=0.01). This association remained when performing logistic regression with age, dose, duration of treatment and sex as covariates (P=0.01). There were almost equal frequencies of the three genotypes in the patients presenting with diabetes, whereas there was an excess of heterozygotes, compared with both homozygotes in those without diabetes. The genotypes of the other marker on this gene, -8933 (A/G), showed no significant association with any of the adverse reactions (P > 0.1 in all analyses).
SLC6A4
The genotype and allele distribution of -15370(A/G) showed no significant association with any of the adverse reactions (P > 0.1 in all analyses). The genotype at LPR 
39 (14) 27 (10) 195 (70) 44 (16) 39 (14) 207 (76) 37 (14) 29 (10) 96 (36) 128 (47) 45 (17) 213 (80 (14) 42 (12) 252 (73) 44 (13) 48 (14) 251 (74) 47 (14) 43 (12) 131 (39) 145 (44) 52 (16) 266 (79) 66 (20) 4 (1) 126 (36) 173 (49) 52 (15) 295 (85) 47 (14) 7 (2) 87 (26) 175 (52) 76 (22) 257 (75) 81 (24) 4 (1) Present 57 (77) 12 (16) 5 (7) 55 (72) 18 (24) 3 (4) 57 (77) 12 (16) 5 (7) 26 (36) 35 (48) 12 (16) 58 (78) 16 (22) 0 2 1 (28) 44 (58) 11 (14) 65 ( yielded a significant association with BMI as a continuous variable (P=0.05), although it became just a trend (P = 0.1) when adding age, dose, duration of treatment and sex as covariates. Significant associations were observed with the dichotomized version of this side effect, that is, the presence or absence of BMI greater than 30 kg/m 2 (P = 0.04 for genotype distribution and P = 0.03 for allele distribution). Of the 198 participants with BMI greater than 30 kg/m 2 , 38 (19.2%) possessed the S/S genotype compared with 11% in the 229 participants with lower BMI. Similarly, the S allele was significantly more frequent in patients presenting with a BMI of greater than 30 kg/m 2 (0.44) than in those with lower BMI (0.37). Haplotype analyses did not reveal a significant influence of the -15370(A/G) polymorphism on this association (see the section Haplotype analysis). Logistic regression including the influencing factors as covariates remained significant, with genotype showing a marginal contribution to high BMI variation (P = 0.08). No further statistically significant association could be detected between the genotypes at the LPR polymorphism and the other adverse reactions as can be seen in Table 2 .
Haplotype analysis
Association analyses results of the four different haplotypes of the two markers on HTR2A with the various adverse reactions were not significant as judged by the likelihood ratio test (LRT) statistic and the probability values (for EPS LRT=1.72 and P=0.63, for TD LRT=1.62 and P=0.65, for high BMI LRT=3.70 and P=0.30, and for diabetes LRT=0.56 and P=0.91). Similarly, no statistically significant association was obtained between the eight haplotypes of the three markers on HTR2C (for EPS LRT=12.34 and P=0.06, for TD LRT=11.64 and P=0.07, for high BMI LRT = 8.86 and P=0.18, for diabetes LRT=6.54 and P=0.37). Adverse reactions were not significantly associated with the haplotypes of the TPH2 gene (for EPS LRT=6.32 and P=0.10, for TD LRT=5.14 and P = 0.16, for high BMI LRT=3.44 and P=0.33, and for diabetes LRT=2.20 and P=0.53). No significant associations were obtained between the four haplotypes of the two markers relating to SLC4A6 and the various side effects (for EPS LRT=3.94 and P=0.27, for TD LRT=2.74 and P=0.43, for high BMI LRT=5.16 and P=0.16, and for diabetes LRT=0.88 and P=0.83).
Discussion
The hypothesis that the serotonergic system genes are involved in mediating adverse reactions to antipsychotics was tested using two serotonin receptor genes (HTR2A and HTR2C), the serotonin transporter gene (SLC6A4) and a gene that exerts a rate-limiting influence on the biosynthesis of serotonin (TPH2).
Of the range of variables tested for association with the two markers on HTR2A, BMI, reflecting body size and composition at the time of measurements rather than weight gain, was significantly associated with the genotypes at the 102 (T/C) marker (P=0.005), independent of the other covariates considered. The higher BMI values seem to be present in those patients possessing two copies of the T allele (P=0.04, refer to Table 2 ). These results do not remain statistically significant if conservative multiple analyses corrections are applied. However, this finding is in broad agreement with the observation by Aubert et al. (2000) that HTR2A gene polymorphisms may influence food and alcohol intake in obese people through the regulatory role of the serotonergic system. In this study, a 5-HT2A -1438 (G/A) polymorphism, which is in nearly complete LD with the 102 (T/C) polymorphism in Caucasians, was investigated. The authors found that the individuals with the -1438-A/A genotype (equivalent to 102-T/T) showed a slightly higher BMI, although not statistically significant, and a lower energy intake. No statistically significant association was found in a sample of clozapine-treated Chinese patients (Hong et al., 2001) , although higher weight gain was observed in 102-T/T individuals. We conclude from these preliminary results, which require replication and monitoring of BMI at different time points during treatment to assess weight gain, that the 102 (T/C) polymorphism of HTR2A may have a moderate influence on the BMI of patients after antipsychotic treatment. Whether it is the 102 (T/C) marker itself, or some other polymorphism in LD with it (e.g. the -1438 (G/A) polymorphism), which leads to this marker-BMI association, remains to be established by functional analysis. Associations of HTR2A polymorphisms and TD reported earlier (Tan et al., 2001; Lattuada et al., 2004; Lerer et al., 2005) were not seen in this study, even when influencing factors such as age, dose, duration of treatment and sex were considered. Other investigators (Basile et al., 2001; Herken et al., 2003) were also unable to replicate any association between HTR2A polymorphisms and TD.
For HTR2C, a trend towards association (P=0.09) of the Cys23Ser marker with the presence of diabetes was attributed to having one or two copies of the Cys allele. Such an association is not well reported in the literature and replication of this initial result is required before further conclusions can be drawn. -995 (G/A) and -759 (C/T) were found in strong LD in our sample, and their genotype distribution showed a trend towards association with the presence of EPS (P=0.08 and 0.06, respectively), although these marginal findings disappeared when age, dose, duration of treatment and sex were included in logistic regression analyses. No associations with BMI and the investigated HTR2C polymorphisms were observed. Earlier studies have found an association between -759 (C/T) and antipsychoticinduced weight gain (Templeman et al., 2005) , although this finding has not been universally replicated Theisen et al., 2004) . This apparent disagreement of findings may be because of the crosssectional nature of our clinical data, as mentioned before.
Markers on the TPH2 gene have in the past yielded significant association with major depression and suicide (Zill et al., 2004a (Zill et al., , 2004b among others. However, to our knowledge no study to date clarifying the link between this gene with response and/or adverse reactions to antipsychotics has been published. The significant genotype association of the -366(T/C) marker on this gene with the presence of diabetes (P=0.01) seems to disappear when carrying out allelic association analysis (P=0.95). Examination of the genotype distribution of this marker in relation to diabetes reveals the presence of excess heterozygotes (52%) compared with both homozygotes (26% for the T/T genotype and 22% for the C/C genotype) in the diabetes-free group. In contrast, patients with diabetes showed almost equal frequencies for the three genotypes (35% for the T/T genotype, 32% for the T/C genotype and 32% for the C/C genotype). This somewhat surprising finding was also observed when age, dose, duration of treatment and sex were included as covariates in logistic regression analyses (P = 0.01). Apart from genotyping error or false-positive finding, being heterozygotic for this marker would appear to be advantageous against developing diabetes as a side effect of treatment with antipsychotics. These polymorphisms are located in the 5 0 promoter region of the TPH2 gene and may influence expression although no study has yet established their functionality. To clarify this finding, replication of this study in an independent cohort, including additional SNPs to achieve better gene coverage, is required.
Of the various adverse reactions analysed in relation to the genotype distribution at the 5-HTT LPR and -15370(A/G) markers of the serotonin transporter gene (SLC6A4), BMI yielded a significant association with the LPR genotype. This marker is in the 5-upstream regulatory region of the serotonin transporter gene and is characterized by a 44 bp insertion/deletion polymorphism leading to long (L-allele) and short (S-allele) variants. The L-allele possesses higher, in-vitro, transcriptional activity compared with the S-allele (Lesch et al., 1996) . The mean BMI values were higher in carriers of the S/S genotype compared with the L/L genotype (P=0.04). Allelic association analysis against the dichotomized BMI values also revealed significant association (P=0.03) of the S allele with the tendency to have higher BMI after antipsychotic treatment. It would appear, therefore, that the lack of sufficient serotonin transporter could be associated with obesity, as judged by BMI, after antipsychotic treatment. However, a study on clozapinetreated Chinese patients found similar weight gain in patients presenting L/L or S/S genotypes but slightly higher baseline weight in patients that were homozygotic for the S variant (Hong et al., 2001) . Ethnic and sample size differences (the latter study might have been underpowered with an N=93) may account for this apparent discrepancy, but further confirmation of this finding is required. Future replication of this study should aim at measuring a weight index over several time points during treatment to confirm any link between this polymorphism and weight gain.
In summary, we found several associations between polymorphisms in genes of the serotonergic system and several treatment-associated clinical variables. Although the significance of these findings is marginal and would not withstand restrictive multiple analyses corrections, they contribute to the mounting evidence suggesting that the serotonergic system is involved in some of the adverse reactions experienced by patients on antipsychotics. Given the limitations of our study (cross-sectional data, moderate sample size and incomplete gene coverage) and the possibility of false positives or negatives in association studies, we have planned replication of these findings in an independent sample, with additional coverage of gene variants to confirm our findings.
